MET and non-small cell lung carcinoma: A phase I trial reported that in addition to KRAS and/or TP53 mutations, the most common concurrent genetic aberrations in NSCLC were CDKN2A, EGFR, BRAF, PIK3CA, ATM, APC, STK11, c-MET and KIT [92].